Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Eugene Batuyong"'
Autor:
Kim Koczka, Rodrigo Rigo, Eugene Batuyong, Sara Cook, Mohammad Asad, Isabelle Vallerand, Aleksi Suo, Edwin Wang, Tina Cheng
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2427-2439 (2023)
Abstract Background Anti‐programmed death‐1 (PD‐1) immunotherapy has drastically improved survival for metastatic melanoma; however, 50% of patients have progression within 6 months despite treatment. In this study, we investigated host, and tu
Externí odkaz:
https://doaj.org/article/b6b0896f2221487c84ee846dcf3c4792
Autor:
Carissa Beaulieu, Arthur Lui, Dimas Yusuf, Zainab Abdelaziz, Brock Randolph, Eugene Batuyong, Sunita Ghosh, Oliver F. Bathe, Vincent Tam, Jennifer L. Spratlin
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 417-427 (2021)
Background: Biliary tract cancers (BTC) are uncommon malignancies and are underrepresented in the literature. Methods: We performed a retrospective population-based review of adult patients with biopsy-confirmed BTC in Alberta from 2000 to 2015. Demo
Externí odkaz:
https://doaj.org/article/0e6e1a15eea34548961566751d9d5b63
Autor:
Mohammed A. Alghamdi, Carla P. Amaro, Richard Lee‐Ying, Hao‐Wen Sim, Haider Samwi, Kelvin K. Chan, Jennifer J. Knox, Yoo‐Joung Ko, Mina Swiha, Eugene Batuyong, Adriana Romagnino, Winson Y. Cheung, Vincent C. Tam, the Hepatocellular Carcinoma ‐ Cancer Health Outcomes Research Database (HCC ‐ CHORD) Consortium
Publikováno v:
Cancer Medicine, Vol 9, Iss 14, Pp 4918-4928 (2020)
Abstract Background Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC), however, full dose can be difficult to tolerate. The aim of this study was to determine whether sorafenib starting dose and mea
Externí odkaz:
https://doaj.org/article/f30b00a8c00b40719fb7ffe444f5c912
Autor:
Andrea S. Fung, Vincent C. Tam, Daniel E. Meyers, Hao‐Wen Sim, Jennifer J. Knox, Valeriya Zaborska, Janine Davies, Yoo‐Joung Ko, Eugene Batuyong, Haider Samawi, Winson Y. Cheung, Richard Lee‐Ying
Publikováno v:
Cancer Medicine, Vol 9, Iss 13, Pp 4640-4647 (2020)
Abstract Background The CELESTIAL, RESORCE, and REACH‐2 trials showed survival benefit of cabozantinib, regorafenib, and ramucirumab, respectively, in hepatocellular carcinoma (HCC) patients treated with sorafenib who had good performance status (E
Externí odkaz:
https://doaj.org/article/f4695cfcaa624e019d0cbdbba425df4f
Autor:
Haider H. Samawi, Hao‐Wen Sim, Kelvin K. Chan, Mohammad A. Alghamdi, Richard M. Lee‐Ying, Jennifer J. Knox, Parneet Gill, Adriana Romagnino, Eugene Batuyong, Yoo‐Joung Ko, Janine M. Davies, Howard J. Lim, Winson Y. Cheung, Vincent C. Tam, the CHORD Consortium
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 2816-2825 (2018)
Abstract Several systems (tumor‐node‐metastasis [TNM], Barcelona Clinic Liver Cancer [BCLC], Okuda, Cancer of the Liver Italian Program [CLIP], and albumin–bilirubin grade [ALBI]) were developed to estimate the prognosis of patients with hepato
Externí odkaz:
https://doaj.org/article/2a723d203a9a4244bf3fd0d5668b1cac
Autor:
Kim Koczka, Rodrigo Rigo, Eugene Batuyong, Sara Cook, Mohammad Asad, Isabelle Vallerand, Aleksi Suo, Edwin Wang, Tina Cheng
Publikováno v:
Cancer Medicine. 12:2427-2439
Anti-programmed death-1 (PD-1) immunotherapy has drastically improved survival for metastatic melanoma; however, 50% of patients have progression within 6 months despite treatment. In this study, we investigated host, and tumor factors for metastatic
Autor:
Sunita Ghosh, Arthur Lui, Zainab Abdelaziz, Eugene Batuyong, Vincent C. Tam, Dimas Yusuf, Oliver F. Bathe, Brock Randolph, Jennifer L. Spratlin, Carissa Beaulieu
Publikováno v:
Current Oncology
Current Oncology, Vol 28, Iss 44, Pp 417-427 (2021)
Volume 28
Issue 1
Pages 44-427
Current Oncology, Vol 28, Iss 44, Pp 417-427 (2021)
Volume 28
Issue 1
Pages 44-427
Background: Biliary tract cancers (BTC) are uncommon malignancies and are underrepresented in the literature. Methods: We performed a retrospective population-based review of adult patients with biopsy-confirmed BTC in Alberta from 2000 to 2015. Demo
Autor:
Yoo-Joung Ko, Winson Y. Cheung, Vincent C. Tam, Eugene Batuyong, Carla P Amaro, Richard M. Lee-Ying, Mohammed Abdulrahman Alghamdi, Jennifer J. Knox, Haider Samwi, Mina Swiha, Kelvin K. W. Chan, Hao-Wen Sim, Adriana Romagnino
Publikováno v:
Cancer Medicine, Vol 9, Iss 14, Pp 4918-4928 (2020)
Cancer Medicine
Cancer Medicine
Background Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC), however, full dose can be difficult to tolerate. The aim of this study was to determine whether sorafenib starting dose and mean dose in
Autor:
Alexander S, Watson, Richard, Gagnon, Eugene, Batuyong, Nimira, Alimohamed, Richard, Lee-Ying
Publikováno v:
Clinical Genitourinary Cancer. 20:496.e1-496.e9
For post-docetaxel treatment of metastatic castrate-resistant prostate cancer (mCRPC), cabazitaxel has demonstrated superior third line PFS and OS compared to androgen receptor pathway inhibitors (ARPIs) in patients who progress within 12 months on f
Publikováno v:
Current Oncology
Volume 27
Issue 4
Pages 5981-203
Volume 27
Issue 4
Pages 5981-203
Venous thromboembolism (vte) in malignancy is associated with poor outcomes. We conducted a retrospective review of vte in patients with endometrial cancer to characterize the vte incidence, identify factors that contribute to vte risk, and compare s